Allena Pharmaceuticals, Inc.
ALNA · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,981 | $7,758 | -$6,583 | $9,024 |
| G&A Expenses | $2,943 | $3,799 | $1,041 | $3,407 |
| SG&A Expenses | $2,943 | $3,799 | $1,041 | $3,407 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,924 | $11,557 | -$5,542 | $12,431 |
| Operating Income | -$8,317 | -$11,564 | $5,227 | -$12,431 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$118 | -$256 | $228 | -$261 |
| Pre-Tax Income | -$8,435 | -$11,813 | $5,455 | -$12,692 |
| Tax Expense | $118 | $249 | -$228 | $0 |
| Net Income | -$8,553 | -$12,062 | $5,683 | -$12,692 |
| % Margin | – | – | – | – |
| EPS | -0.085 | -0.13 | 0.074 | -0.17 |
| % Growth | 34.6% | -275.4% | 143.6% | – |
| EPS Diluted | -0.085 | -0.13 | 0.074 | -0.17 |
| Weighted Avg Shares Out | 100,624 | 89,383 | 76,658 | 76,658 |
| Weighted Avg Shares Out Dil | 100,624 | 89,383 | 76,658 | 76,658 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $118 | $249 | -$228 | $250 |
| Depreciation & Amortization | $118 | $125 | $122 | $96 |
| EBITDA | -$9,592 | -$11,439 | $5,349 | -$12,346 |
| % Margin | – | – | – | – |